secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuphoria Therapeutics Inc. (NEUP)
CIK:        0001191070
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001213900-25-045970
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuphoria Q1 update: BNC-210 Phase 3 topline due Q3 2025; cash runway into Q3 2026
--------------------------------------------------------------------------------

- Cash runway extends into Q3 2026; no near-term financing risk stated.
- Phase 3 AFFIRM-1 trial of BNC-210 for social anxiety disorder on track for topline readout in Q3 2025.
- Partnered α7 nAChR PAM MK-1167 (Merck) in Phase 2 for Alzheimer's disease.
- Phase 2b SYMPHONY trial for BNC-210 in PTSD planned after positive FDA End-of-Phase 2 meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1191070/000121390025045970/0001213900-25-045970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1191070/000121390025045970/ea0242929-8k_neuphoria.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-045970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer